A Tolerability and Pharmacokinetic Study of Adjuvant Erlotinib and Capecitabine with Concurrent Radiation in Resected Pancreatic Cancer

BACKGROUND: Erlotinib is approved for the treatment of advanced pancreas cancer. We conducted a prospective trial to determine the safety profile and recommended phase 2 dose of erlotinib and capecitabine given concurrently with intensity-modulated radiation therapy (IMRT) in resected pancreatic can...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Ma, Wen Wee, Herman, Joseph M, Jimeno, Antonio, Laheru, Daniel, Messersmith, Wells A, Wolfgang, Christopher L, Cameron, John L, Pawlik, Timothy M, Donehower, Ross C, Rudek, Michelle A, Hidalgo, Manuel
Format: Artigo
Idioma:Inglês
Publicat: Neoplasia Press Inc. 2010
Matèries:
Research Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC3000462/
https://ncbi.nlm.nih.gov/pubmed/21151476
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars